Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon

Brito, Marcelo Augusto Mota; Peixoto, Henry Maia; Almeida, Anne Cristine Gomes de; Oliveira, Maria Regina Fernandes de; Romero, Gustavo Adolfo Sierra; Moura-Neto, J.P.; Singh, Nakul; Monteiro, Wuelton Marcelo; Lacerda, Marcus Vinícius Guimarães

doi:10.1590/0037-8682-0134-2016

Cited by 26 publications

(27 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although CareStart™ G6PD rapid test has been demonstrated to have > 95% sensitivity in detecting G6PD deficient phenotypes [5][6][7][8] , there have been discrepant results. Particularly, low sensitivity among individuals with enzyme activity < 30% has been reported in Cambodia (68%) 9 and more recently in the Brazilian Amazon (61.5%) 10 .…”

Section: Dear Editormentioning

confidence: 99%

“…However, no mention of a pale purple color background appeared in the first batches of CareStart TM G6PD manufacturer's instructions 11 . As a result, a pale purple background was classified as normal only by the Cambodian study, and later by the Brazilian study 9,10 . The most recent CareStart TM G6PD test instructions indicate that no color change or the appearance of a very faint purple color in the reading window within 10 min (borderline results) should be read as deficient 12 .…”

Section: Dear Editormentioning

confidence: 99%

See 1 more Smart Citation

Accuracy of CareStart™ G6PD rapid diagnostic test: variation in results from different commercial versions

Monteiro

Brito

Lacerda

2017

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

Section: Dear Editormentioning

confidence: 99%

Section: Dear Editormentioning

confidence: 99%

Accuracy of CareStart™ G6PD rapid diagnostic test: variation in results from different commercial versions

Monteiro

Brito

Lacerda

2017

Rev. Soc. Bras. Med. Trop.

Self Cite

View full text Add to dashboard Cite

“…The most widely used lateral flow assay is the CareStart G6PD RDT (Accessbio, USA) with operational characteristics suitable for application in the field [6]. The test has been evaluated thoroughly and in most cases found to perform comparably to the FST [34–38]. It has a similar cut-off activity to the FST and hence it is not suitable for guiding treatment with TQ [6] however its superior operational characteristics and price [6, 37] make it a useful alternative to the FST prior to PQ treatment.…”

Section: Topic 2: Necessary Properties Of G6pd Test For Wide Scale Dementioning

confidence: 99%

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group

Thriemer¹,

Ley²,

Bobogare³

et al. 2017

Malar J

View full text Add to dashboard Cite

The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving malaria elimination from the Asia–Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimination Network Vivax Working Group in October 2016, a round table discussion was held to discuss the programmatic issues hindering the widespread use of primaquine (PQ) radical cure. Participants included 73 representatives from 16 partner countries and 33 institutional partners and other research institutes. In this meeting report, the key discussion points are presented and grouped into five themes: (i) current barriers for glucose-6-phosphate deficiency (G6PD) testing prior to PQ radical cure, (ii) necessary properties of G6PD tests for wide scale deployment, (iii) the promotion of G6PD testing, (iv) improving adherence to PQ regimens and (v) the challenges for future tafenoquine (TQ) roll out. Robust point of care (PoC) G6PD tests are needed, which are suitable and cost-effective for clinical settings with limited infrastructure. An affordable and competitive test price is needed, accompanied by sustainable funding for the product with appropriate training of healthcare staff, and robust quality control and assurance processes. In the absence of quantitative PoC G6PD tests, G6PD status can be gauged with qualitative diagnostics, however none of the available tests is currently sensitive enough to guide TQ treatment. TQ introduction will require overcoming additional challenges including the management of severely and intermediately G6PD deficient individuals. Robust strategies are needed to ensure that effective treatment practices can be deployed widely, and these should ensure that the caveats are outweighed by the benefits of radical cure for both the patients and the community. Widespread access to quality controlled G6PD testing will be critical.

show abstract

“…Spectrophotometry is the gold standard test of G6PD activity, but requires specialised staff and laboratory facilities [48,49]. Until recently, the only point-of-care test for G6PD deficiency was the fluorescent spot test (FST).…”

Section: Screening For G6pd Deficiency and Future Options For Radicalmentioning

confidence: 99%

The Economics of Vivax Malaria Treatment

Devine¹

2018

Preprint

View full text Add to dashboard Cite

The control and eventual elimination of malaria will require widescale adoption of strategies to ensure early diagnosis and highly effective treatment of infected individuals. In Plasmodium vivax, multiple relapse episodes can only be averted by treating the dormant liver stage of the parasite life cycle -a strategy known as radical cure. This thesis aims to investigate key factors determining treatment-seeking behaviour and costs associated with vivax malaria, how these influence healthcare decisions, the cost-effectiveness of screening tests and treatments for radical cure, and the cost-benefit implications of their global implementation.Treatment-seeking behaviour, assessed in Papua, Indonesia, demonstrated that household costs per person seeking treatment for vivax malaria were similar to those for falciparum malaria. Switching from ineffective to effective malaria treatment in the public sector improved the behaviour of patients and both public and private healthcare providers. Diagnostic strategies were investigated on the Thai-Myanmar border, where screening for glucose-6-phosphate-dehydrogenase (G6PD) deficiency prior to radical cure reduced the disease burden while being a cost-effective option for healthcare providers that do not use radical cure and a potentially cost-saving alternative where primaquine is prescribed without screening. The costs of implementing G6PD screening were collected in three countries, and highlighted that RDTs consistently reduced costs as compared to the widely-used fluorescent spot test. Across four countries, the indirect cost due to lost productivity was the largest cost component for households of patients with vivax malaria. After combining provider and patient costs with case estimates, the global economic burden of vivax malaria was estimated to be US$330 million per year. Adopting a policy of screening for G6PD deficiency with delivery of highly effective radical cure was projected to save US$45 million.P. vivax malaria causes a large economic burden that can be reduced substantially by delivering safe and effective radical cure.iii iv

show abstract

Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon

Cited by 26 publications

References 40 publications

Accuracy of CareStart™ G6PD rapid diagnostic test: variation in results from different commercial versions

Accuracy of CareStart™ G6PD rapid diagnostic test: variation in results from different commercial versions

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group

The Economics of Vivax Malaria Treatment

Contact Info

Product

Resources

About